Small molecule inhibitors of the phosphatidylinositol 3-kinase (PI3K), Akt and mTOR pathway currently in the clinic produce a paradoxical reactivation of the pathway they are intended to suppress. Furthermore, fresh experimental evidence with PI3K antagonists in melanoma, glioblastoma and prostate cancer shows that mitochondrial metabolism drives an elaborate process of tumor adaptation culminating with drug resistance and metastatic competency. This is centered on reprogramming of mitochondrial functions to promote improved cell survival and to fuel the machinery of cell motility and invasion. Key players in these responses are molecular chaperones of the Heat Shock Protein 90 (Hsp90) family compartmentalized in mitochondria, which suppress apoptosis via phosphorylation of the pore component, Cyclophilin D, and enable the subcellular repositioning of active mitochondria to membrane protrusions implicated in cell motility. An inhibitor of mitochondrial Hsp90s in preclinical development (Gamitrinib) prevents adaptive mitochondrial reprogramming and shows potent anti-tumor activity in vitro and in vivo. Other therapeutic strategies to target mitochondria for cancer therapy include small molecule inhibitors of mutant isocitrate dehydrogenase (IDH) IDH1 (AG-120) and IDH2 (AG-221) which opened new therapeutic prospects for high-risk AML patients. A second approach of mitochondrial therapeutics focuses on agents that elevate toxic ROS levels from a leaky electron transport chain, nevertheless the clinical experience with these compounds, including a quinone derivative, ARQ 501, and a copper chelator, elesclomol (STA-4783) is limited. In light of these evidences, we discuss how best to target a resurgence of mitochondrial bioenergetics for cancer therapy.
On the other hand, the dichotomy between glycolysis and oxidative phosphorylation in cancer bioenergetics may not be as rigid as previously thought. In fact, we know that mitochondria remain fully functional in most tumors (11) , oxidative phosphorylation still accounts for a large fraction of ATP produced in cancer (12) , and even under conditions of severe hypoxia, cytochromes are fully oxidized to support cellular respiration (13) . This biochemical evidence fits well with a flurry of functional data that point to oxidative phosphorylation as an important cancer driver (Table 1) . Accordingly, mitochondrial respiration contributes to oncogene-dependent transformation (14) and metabolic reprogramming (15), supports energy-intensive mechanisms of protein translation in tumors (16) , maintains cancer "stemness" (17) , favors malignant repopulation after oncogene ablation (18) , and promotes the emergence of drug resistance (19) ( Table 1 summarizes the mitochondrial pathways involved in cancer and the effect of targeting such pathways). In addition, there is evidence that oxidative phosphorylation may be required to support tumor cell motility (20) and metastasis (21) , potentially under conditions of stress or limited nutrient availability. Mechanistic aspects of how tumors may regulate oxidative phosphorylation have also come into better focus, pointing to a key role of protein folding quality control maintained by mitochondria-localized Heat Shock Protein-90 (Hsp90) chaperones (22) , as well as organelle proteases (23) of mtHsp90 led to 80% reduction in breast cancer metastasis to bone (20) . Furthermore, OxPhos impairment after shRNA silencing of the mitochondrial biomass factor PGC-1α inhibited breast cancer metastasis to lung by 70-90% (21) . On the contrary, activation of autophagy by expression of a constitutively active mutant of AMPK or ULK1 impaired lung cancer metastasis to liver (60-80% reduction) (20) .
Mitochondria and tumor adaptation.
Against this more composite backdrop, where tumor metabolism dynamically integrates both glycolysis and oxidative phosphorylation, new evidence has uncovered an unexpected role of mitochondria in tumor adaptation to molecular therapy. We have known for some time that exposure of tumors to small molecule inhibitors of the phosphatidylinositol 3-kinase (PI3K) (24), Akt and mTOR pathway currently in the clinic, produce a paradoxical reactivation of the pathway they are intended to suppress (25) (26) (27) . What was not known was the impact (if any) of this response on disease behavior. Now, more recent studies demonstrated that molecular therapy with PI3K antagonists induced transient metabolic quiescence with reduced oxygen and glucose consumption rates, while promoting the redistribution of active Akt, mostly Akt2 from cytosol to 
CLINICAL-TRANSLATIONAL ADVANCES
Altogether, the reshaped research landscape summarized above points to mitochondria as a hub of tumor responses, and important therapeutic target in cancer (32) . This concept has been successfully pursued with the clinical development of modulators of apoptosis, a process regulated at the outer mitochondrial membrane (29) . But the idea of targeting mitochondrial metabolism, let alone mechanisms of mitochondrial adaptation for cancer therapeutics is still in its infancy (32) .
Even therapeutic efforts to disable well-established glycolytic pathways in tumors (11, 33, 34) showed an 80% objective response rate (ORR) of TH-070 in combination with paclitaxel and cisplatin (35) . A Phase II trial in 31 patients with NSCLC who were treated with TH-070 in combination with cisplatin, epidoxorubicin and vindesine showed 89% of patients had either a partial remission (PR) or stable disease (SD) (35) . Despite this early promising trials, TH-070 development was terminated after disappointing results in two randomized Phase III trials (35) . A second agent that prevents glycolysis, 2-deoxyglucose (2-DG), a non-metabolizable glucose analog was also pursued in the clinic. However, dose escalation Phase I trials in patients with castrate-resistant prostate cancer and other advanced solid tumors resulted in asymptomatic QTc prolongation that limited further drug evaluation (35) .
An independent approach involved therapeutic inhibition of pyruvate dehydrogenase kinase (PDK1) with the small molecule antagonist dichloroacetate (DCA). PDK1 is a recognized therapeutic target in cancer (36) given its ability to phosphorylate and inhibit the Pyruvate Dehydrogenase Complex (PDC), thus preventing the decarboxylation of pyruvate to Acetyl-CoA and its subsequent entry in the tricarboxylic acid cycle (37) . Clinical trials (Phase I) with DCA in glioma patients revealed manageable tolerability and hints of objective responses (38) . Although a phase II trial of DCA in non-small cell lung cancer was stopped early due to treatment-related deaths and lack of clinical benefit (39), encouraging preclinical results were reported for the combination of DCA plus 5-FU and cisplatin in gastric cancer (35) . DCA is being currently evaluated in patients with head and neck cancer, glioblastoma and other solid tumors. The preclinical development of Gamitrinib in anticipation of human testing is now progressing as an academic endeavor. In addition to general issues of formulation (like its parent compound, 17-AAG, Gamitrinib is water-insoluble) and dosing, critical questions of tolerability for normal tissues that are dependent on mitochondrial respiration are of top priority, even though preclinical data have suggested a manageable toxicity profile in mice. Of key relevance are also opportunities for combination therapy with cytotoxics or molecular agents (46) . In this context, the unique "mitochondriotoxic" mechanism of action of Gamitrinib (44) may be ideally suited to counter therapy-induced tumor adaptation as a driver of disease progression (28, 30) .
Recent evidence seems to validate this premise, as sub-therapeutic concentrations of Gamitrinib reversed mitochondrial reprogramming induced by PI3K antagonists, blocked the recruitment of mitochondria to the cortical cytoskeleton in these settings, and suppressed tumor cell invasion (20, 30) , and metastasis (47) . This may create tangible opportunities for repurposing agents that have shown limited activity in the clinic, as Gamitrinib potently synergized with PI3K therapy in a high-throughput drug combination screen, converting a transient, cytostatic effect into potent, cytotoxic anticancer activity (28, 30) . In these experiments, the combination Gamitrinib and a PI3K/mTOR inhibitor (BEZ235) extended animal survival in a glioblastoma model (vehicle: median survival = 28.5 days; Gamitrinib+PI3Ki: median survival = 40 days, P = 0.003), compared with single-agent treatment (PI3Ki: median survival = 32 days, P = 0.02; Gamitrinib: median survival = 35 days, P = 0.008).
CONCLUDING REMARKS
Research. 
